Expert Interview
A look at Global Blood Therapeutics' Sickle Cell disease therapeutics including the continued use of Oxbryta and the potential of inclacumab
Ticker(s): GBTInstitution: Private Practice
- Physician specializing in Hematology and Oncology
- Treats many patients for sickle cell disease and is very familiar with the current treatment landscape as well as drugs in development.
- Active within the hematology community and will be attending the upcoming European Hematology Association conference in Vienna this year.
Could you please describe your clinical practice including how many patients you treat for sickle cell disease and how many you have prescribed Oxbryta for?
Added By: sara_adminCan you speak about your clinical experience with your patients on Oxbyta?
Added By: sara_adminWhat are your initial thoughts on the abstract of inclacumab?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
